THE SGLT2 INHIBITOR EMPAGLIFLOZIN IMPROVES DIASTOLIC FUNCTION IN A HEART FAILURE MODEL MEDIATED VIA ENHANCED MYOCARDIAL KETONE METABOLISM

The SGTL2 inhibitor empagliflozin (Empa) reduces HF. We have recently demonstrated 1) the mechanism is due to a switch in myocardial metabolism towards ketone bodies (KB) consumption; and 2) KB infusion improves LV systolic function in a porcine HF model. However, there is no information about the